Phospholipid Syndrome Profile at Chughtai Lab

Understanding the Phospholipid Syndrome Profile at Chughtai Lab

The Phospholipid Syndrome Profile is a comprehensive panel of specialized laboratory investigations designed to detect the presence of antiphospholipid antibodies (aPL) in the blood. These autoantibodies mistakenly target the body’s own cell membrane proteins, specifically those bound to anionic phospholipids. This autoimmune activity can trigger abnormal blood clotting (thrombosis) in both arteries and veins, as well as lead to significant pregnancy-related complications, including recurrent miscarriages and preeclampsia. This clinical condition is medically recognized as Antiphospholipid Syndrome (APS) or Hughes Syndrome.

At Chughtai Lab, this profile is executed using advanced immunological and coagulation methodologies to ensure the highest degree of diagnostic accuracy. The profile typically comprises three primary tests: the Lupus Anticoagulant (LA) assay, Anti-Cardiolipin (aCL) antibodies (IgG and IgM), and Anti-Beta-2 Glycoprotein I (aβ2GPI) antibodies (IgG and IgM). Evaluating these markers simultaneously is clinically vital because the presence of multiple antibody types—often referred to as double or triple positivity—significantly increases a patient’s risk of thrombotic events and obstetric complications.

Understanding the pathophysiology of APS is essential for appreciating the diagnostic value of this profile. In a healthy individual, phospholipids serve as structural components of cell membranes and play a key role in regulating coagulation. In patients with APS, the immune system produces autoantibodies that bind to plasma proteins like beta-2 glycoprotein I or prothrombin when they associate with phospholipid surfaces. This binding activates endothelial cells, platelets, and monocytes, shifting the vascular environment toward a prothrombotic state. By identifying these specific antibodies, the Phospholipid Syndrome Profile at Chughtai Lab provides clinicians with the objective data needed to diagnose APS, assess thrombotic risk, and formulate effective long-term anticoagulation or obstetric management strategies.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the accuracy of the Phospholipid Syndrome Profile, patients must adhere to specific preparation guidelines. Because certain components of the profile rely on coagulation assays, preparation is more detailed than that of a standard blood draw:

• Anticoagulant Therapy Disclosure: It is absolutely critical to inform the laboratory staff and your referring physician if you are currently taking any blood thinners, such as Warfarin, Heparin, Low-Molecular-Weight Heparin (LMWH), or Direct Oral Anticoagulants (DOACs) like Rivaroxaban or Apixaban. These medications can interfere with the clotting-based assays used to detect Lupus Anticoagulant, potentially leading to false-positive or uninterpretable results.
• Timing of the Test: If you are being tested to confirm a previous positive result, the test must be scheduled at least 12 weeks after the initial test. This delay is necessary to distinguish between transient antibodies (often caused by temporary infections) and persistent autoantibodies indicative of true APS.
• Fasting Requirements: Generally, strict fasting is not required for this profile. However, a light meal is recommended, and patients should avoid excessively fatty foods immediately before the blood draw, as lipemic blood samples can interfere with certain optical clotting assays.
• Hydration: Adequate hydration is encouraged, as it makes venipuncture easier and helps ensure a smooth blood draw.
• Medication Management: Do not stop any prescribed medications, especially anticoagulants, unless explicitly instructed to do so by your treating physician.

During the Procedure

The Phospholipid Syndrome Profile is performed on a blood sample obtained via standard venipuncture. The procedure is quick, safe, and conducted by experienced phlebotomists at Chughtai Lab:

• Patient Positioning: You will be asked to sit comfortably in a blood collection chair. The phlebotomist will ask you to extend your arm, exposing the inner elbow area (antecubital fossa).
• Site Selection and Sanitization: The phlebotomist will inspect your veins and select an appropriate site. The area is then thoroughly cleansed with an antiseptic solution (usually 70% isopropyl alcohol) and allowed to air dry to prevent hemolysis of the sample.
• Tourniquet Application: A tourniquet is applied a few inches above the selected site to increase venous pressure, making the vein more visible and accessible.
• Sample Collection: A sterile, single-use needle is gently inserted into the vein. Chughtai Lab utilizes a vacuum tube system (Vacutainer) to collect the precise volume of blood required. Multiple tubes will be drawn: typically a light-blue top tube containing sodium citrate for the Lupus Anticoagulant clotting assays, and a red or gold-top serum separator tube for the ELISA-based antibody tests.
• Needle Removal and Hemostasis: Once the tubes are filled, the tourniquet is released, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to stop any bleeding. A bandage is then applied.
• Duration and Experience: The entire venipuncture process takes less than five minutes. You may feel a brief pinch or stinging sensation as the needle enters the skin. Some minor bruising at the site is possible but typically resolves within a few days.

When is a Phospholipid Syndrome Profile Performed?

Investigation of Unexplained Blood Clots (Thrombosis)

Physicians frequently request a Phospholipid Syndrome Profile when a patient experiences one or more unexplained blood clots in the veins or arteries. This includes Deep Vein Thrombosis (DVT) in the legs, Pulmonary Embolism (PE) in the lungs, or arterial thromboses leading to premature stroke or myocardial infarction, particularly in individuals under the age of 50 who lack traditional cardiovascular risk factors. Identifying antiphospholipid antibodies helps determine if an autoimmune mechanism is driving the hypercoagulable state, which directly influences the duration and intensity of subsequent anticoagulant therapy.

Recurrent Pregnancy Loss and Obstetric Complications

In obstetrics, this profile is a cornerstone of the diagnostic workup for recurrent pregnancy complications. It is indicated for women who have experienced three or more unexplained, consecutive spontaneous abortions before the 10th week of gestation, one or more unexplained fetal deaths of a morphologically normal fetus at or beyond the 10th week, or one or more premature births before the 34th week due to severe preeclampsia, eclampsia, or placental insufficiency. Detecting these antibodies allows obstetricians to initiate preventative therapies, such as low-dose aspirin and low-molecular-weight heparin, to improve pregnancy outcomes.

Evaluation of Coexisting Autoimmune Disorders

Antiphospholipid Syndrome can occur as a primary condition or secondary to other systemic autoimmune diseases, most notably Systemic Lupus Erythematosus (SLE). Approximately 30% to 40% of patients diagnosed with SLE also test positive for antiphospholipid antibodies. Clinicians order this profile for patients with established autoimmune diseases to risk-stratify them for thrombotic events, as the presence of these antibodies significantly alters the clinical management plan and necessitates proactive monitoring.

Investigation of Unexplained Prolonged Activated Partial Thromboplastin Time (aPTT)

Occasionally, a routine pre-operative coagulation screen may reveal an unexplained prolongation of the Activated Partial Thromboplastin Time (aPTT). Paradoxically, while Lupus Anticoagulant causes blood to clot more easily in the body (in vivo), it interferes with the phospholipid reagents used in laboratory clotting tests, thereby prolonging the clotting time in the test tube (in vitro). When a prolonged aPTT cannot be explained by factor deficiencies or heparin contamination, a Phospholipid Syndrome Profile is performed to confirm or rule out the presence of Lupus Anticoagulant.

Confirmation and Monitoring of Previous Positive Results

According to international consensus criteria (the Sydney criteria), a single positive test for antiphospholipid antibodies is insufficient for a definitive diagnosis of APS. Transient antibodies can appear during acute viral, bacterial, or parasitic infections. Therefore, when a patient tests positive, physicians must repeat the Phospholipid Syndrome Profile at least 12 weeks later. This repeat testing is essential to confirm the persistence of these autoantibodies, which is the hallmark of true Antiphospholipid Syndrome.

What Does a Phospholipid Syndrome Profile Detect?

The Phospholipid Syndrome Profile is designed to detect and quantify several specific markers and clinical parameters. The comprehensive panel evaluates:

• Lupus Anticoagulant (LA): An immunoglobulin that prolongs phospholipid-dependent coagulation assays.
• Dilute Russell’s Viper Venom Time (dRVVT) Screen: A primary screening test that activates Factor X directly, sensitive to the presence of Lupus Anticoagulant.
• dRVVT Confirm Ratio: A confirmatory step where excess phospholipid is added to neutralize the Lupus Anticoagulant, proving phospholipid dependence.
• Silica Clotting Time (SCT): An alternative phospholipid-dependent screening and confirmatory assay used to detect Lupus Anticoagulant.
• Anti-Cardiolipin IgG Antibodies: Autoantibodies directed against cardiolipin-protein complexes, strongly associated with thrombosis and pregnancy loss.
• Anti-Cardiolipin IgM Antibodies: Often detected alongside IgG, representing an active or acute autoimmune response.
• Anti-Beta-2 Glycoprotein I IgG Antibodies: Highly specific markers for clinical APS, targeting the primary cofactor protein involved in pathogenic clotting.
• Anti-Beta-2 Glycoprotein I IgM Antibodies: Antibodies associated with an increased risk of arterial and venous thrombotic events.
• Antibody Titer Levels: The quantitative concentration of antibodies, classified as low, medium, or high positive.
• Persistent Antibody Presence: Confirmation of antibody positivity across two separate blood draws spaced at least 12 weeks apart.
• Triple Positivity: The simultaneous presence of Lupus Anticoagulant, anti-cardiolipin, and anti-beta-2 glycoprotein I antibodies, indicating the highest clinical risk.
• Double Positivity: The presence of two out of the three primary antiphospholipid markers.
• Single Positivity: The presence of only one marker, which may carry a lower but still significant clinical risk.
• Transient Positivity: Temporary antibody elevation caused by acute infections or drug exposure rather than chronic APS.
• In Vitro Coagulation Prolongation: The laboratory phenomenon where the blood sample takes longer to clot in specific screening assays.
• Phospholipid Correction: The normalization of prolonged clotting times upon the addition of extra phospholipids, confirming the presence of a phospholipid-dependent inhibitor.
• Coexisting Thrombocytopenia: Mild to moderate reduction in platelet count, a common hematological finding associated with APS.
• False-Positive Syphilis Serology: A historical diagnostic clue where anti-cardiolipin antibodies cause a false-positive result on VDRL or RPR tests.
• Primary Antiphospholipid Syndrome: Diagnostic evidence of APS occurring in the absence of any other underlying autoimmune disease.
• Secondary Antiphospholipid Syndrome: Diagnostic evidence of APS occurring in association with another autoimmune condition, such as Systemic Lupus Erythematosus (SLE).

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing accurate and timely diagnostic services. Because the Phospholipid Syndrome Profile involves complex, multi-step coagulation assays and specialized ELISA testing, the turnaround time is typically 24 to 48 hours from the time of sample collection. This allows our consultant pathologists to carefully review and correlate the screening and confirmatory phases of the Lupus Anticoagulant testing, ensuring absolute diagnostic precision.

Once your results are finalized and verified by our pathology experts, Chughtai Lab offers multiple convenient ways to access your reports. Patients receive an automated SMS notification containing a direct link to view and download the PDF report. Reports can also be accessed securely through the official Chughtai Lab website by entering your patient ID and password, or via the Chughtai Healthcare mobile application. For added convenience, physical copies of reports can be collected from any Chughtai Lab collection center nationwide, or you can opt to have them delivered directly to your email or via WhatsApp.

Phospholipid Syndrome Profile Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Lupus Anticoagulant (LA) Screen (dRVVT)	Negative (Normal clotting time)	Positive (Prolonged clotting time, suggesting presence of LA)
dRVVT Confirm Ratio	< 1.2 (No significant correction)	≥ 1.2 (Correction of clotting time with phospholipid, confirming LA)
Anti-Cardiolipin IgG	< 15 GPL units (Negative)	≥ 15 GPL units (Positive; medium to high titers indicate increased risk)
Anti-Cardiolipin IgM	< 15 MPL units (Negative)	≥ 15 MPL units (Positive; associated with acute or transient states)
Anti-Beta-2 Glycoprotein I IgG	< 20 SGU (Negative)	≥ 20 SGU (Positive; highly specific for clinical APS and thrombosis)
Anti-Beta-2 Glycoprotein I IgM	< 20 SMU (Negative)	≥ 20 SMU (Positive; indicates elevated risk of thrombotic events)
Activated Partial Thromboplastin Time (aPTT)	Within normal reference range (25-35 seconds)	Prolonged aPTT (not corrected by mixing studies, indicating inhibitor)
Platelet Count (CBC)	Normal (150,000 – 450,000 /μL)	Thrombocytopenia (< 150,000 /μL; common secondary finding in APS)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Phospholipid Syndrome Profile?

• Experienced Healthcare Professionals: Our laboratories are staffed by highly qualified medical technologists and overseen by consultant pathologists specializing in hematology and immunology.
• Patient-Focused Care: We prioritize patient comfort and convenience, ensuring a seamless experience from sample collection to report delivery.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent internal quality control protocols and participates in international external quality assurance programs.
• Professional Reporting: Our reports are detailed, structured, and easy for clinicians to interpret, facilitating rapid clinical decision-making.
• Modern Diagnostic Approach: We utilize state-of-the-art automated analyzers and advanced methodologies for ELISA and coagulation testing.
• Comfortable Environment: All our collection centers are designed to provide a clean, hygienic, and welcoming environment for patients.
• Convenient Location: With an extensive network of collection centers across Pakistan, finding a Chughtai Lab near you is simple and accessible.
• Commitment to Accurate Diagnosis: We understand the critical nature of autoimmune and coagulation testing, ensuring every sample is processed with the highest precision.